L858r | List of Frontiers open access articles

Original Research

Published on 23 Nov 2022

An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy

in Cancer Immunity and Immunotherapy

Jing Lin
Jun Liu
Shi-guang Hao
Bin Lan
Xiao-bin Zheng
Jia-ni Xiong
Ying-qian Zhang
Xuan Gao
Chuan-ben Chen
Ling Chen

Frontiers in Immunology

doi 10.3389/fimmu.2022.1022598

7,486 views
11 citations

Original Research

Published on 25 Aug 2020

Mutant Proteomics of Lung Adenocarcinomas Harboring Different EGFR Mutations

in Molecular and Cellular Oncology

Toshihide Nishimura
Ákos Végvári
Haruhiko Nakamura
Harubumi Kato
Hisashi Saji

Frontiers in Oncology

doi 10.3389/fonc.2020.01494

7,800 views
11 citations

Original Research

Published on 30 May 2022

Uncovering the Mechanism of Drug Resistance Caused by the T790M Mutation in EGFR Kinase From Absolute Binding Free Energy Calculations

in Molecular Recognition

Huaxin Zhou
Haohao Fu
Han Liu
Xueguang Shao
Wensheng Cai

Frontiers in Molecular Biosciences

doi 10.3389/fmolb.2022.922839

4,390 views
13 citations

Original Research

Published on 24 Mar 2023

Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma

in Cancer Immunity and Immunotherapy

Young Wha Koh
Bumhee Park
Se Hee Jung
Jae-Ho Han
Seokjin Haam
Hyun Woo Lee

Frontiers in Immunology

doi 10.3389/fimmu.2023.1137880

4,586 views
4 citations

Original Research

Published on 09 Sep 2025

Coupling enzymatic digestion with nanopore sensing for low-abundance EGFR-L858R mutation detection

in Nanobiotechnology

Ling Yan
Zhenxin Wang
Yajie Yin
Changchun Niu
Yang Luo

Frontiers in Bioengineering and Biotechnology

doi 10.3389/fbioe.2025.1602494

1,948 views

Case Report

Published on 13 May 2025

Case Report: Peritoneal and small bowel metastasis from lung adenocarcinoma with EGFR L858R mutation

in Cancer Imaging and Image-directed Interventions

Tian Tan
Yuerong Huang
Rongxin Yan
Ying Liu

Frontiers in Oncology

doi 10.3389/fonc.2025.1423520

2,090 views
1 citation

Original Research

Published on 02 Jun 2023

Deciphering the molecular mechanism of enhanced tumor activity of the EGFR variant T790M/L858R using melanoma cell lines

in Cancer Molecular Targets and Therapeutics

Hanshuang Shao
Alan Wells

Frontiers in Oncology

doi 10.3389/fonc.2023.1163504

3,334 views
2 citations

Case Report

Published on 26 May 2022

Long-Term Clinical Benefit in EGFR-Mutant Lung Adenocarcinoma With Local Squamous Cell Carcinoma Transformation After EGFR TKI Resistance: A Case Report

in Thoracic Oncology

Junru Ye
Yutong Ma
Qiuxiang Ou
Junrong Yan
Bin Ye
Yuping Li

Frontiers in Oncology

doi 10.3389/fonc.2022.883367

4,539 views
6 citations

Case Report

Published on 11 Jun 2021

Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation

in Molecular and Cellular Oncology

Rossella Bruno
Marzia Del Re
Federico Cucchiara
Iacopo Petrini
Greta Alì
Stefania Crucitta
Agnese Proietti
Simona Valleggi
Antonio Chella
Romano Danesi

Frontiers in Oncology

doi 10.3389/fonc.2021.674604

3,259 views
5 citations

Case Report

Published on 06 May 2024

Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report

in Thoracic Oncology

Petros Christopoulos
Franziska Herster
Petra Hoffknecht
Markus Falk
Markus Tiemann
Hans-Georg Kopp
Andre Althoff
Anja Stammberger
Eckart Laack

Frontiers in Oncology

doi 10.3389/fonc.2024.1347742

4,309 views
1 citation

Case Report

Published on 25 Mar 2024

Case report: EGFR fusion mutation combined with EGFR amplification responds to EGFR-TKI therapy

in Thoracic Oncology

Zhulin Wang
Chunyao Huang
Wenbo Fan
Shaowu Sun
Kaiyuan Li
Xu Liu
Jiangtao Pu
Guoqing Zhang
Xiangnan Li

Frontiers in Oncology

doi 10.3389/fonc.2024.1347282

3,499 views

Original Research

Published on 18 Apr 2024

Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors

in Thoracic Oncology

Balazs Halmos
Pragya Rai
Jae Min
Xiaohan Hu
Diana Chirovsky
Mark Shamoun
Bin Zhao

Frontiers in Oncology

doi 10.3389/fonc.2024.1285280

3,738 views
5 citations

Case Report

Published on 13 Oct 2023

Lung adenocarcinoma in a patient with Lynch syndrome: a case report and literature review

in Cancer Genetics

Alan Hodges
Kai Sun
Tiffany G. Sheu
Eric H. Bernicker

Frontiers in Oncology

doi 10.3389/fonc.2023.1193503

4,057 views
3 citations

Case Report

Published on 09 Aug 2024

Long term survival achieved through combination of almonertinib and pyrotinib in EGFR-mutant/HER2-amplified advanced NSCLC patient: a case report and literature review

in Thoracic Oncology

Xin Pan
Xiao Zhou

Frontiers in Oncology

doi 10.3389/fonc.2024.1397238

2,694 views
2 citations

Review

Published on 11 Jun 2024

The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation

in Thoracic Oncology

Xiuyue Man
Xueru Sun
Chen Chen
Yan Xiang
Jing Zhang
Lei Yang

Frontiers in Oncology

doi 10.3389/fonc.2024.1367204

4,696 views
5 citations

Case Report

Accepted on 12 Feb 2026

Acquired EGFR L858R mutation following ALK-TKI resistance in lung adenocarcinoma: a Case Report

in Thoracic Oncology

Chunxiang LUO
Wenying Peng
Ruying Duan
Runxiang Yang
Susu Qu
Mengyuan Dong
Ruofan Chen

Frontiers in Oncology

Articles

An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy

Mutant Proteomics of Lung Adenocarcinomas Harboring Different EGFR Mutations

Uncovering the Mechanism of Drug Resistance Caused by the T790M Mutation in EGFR Kinase From Absolute Binding Free Energy Calculations

Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma

Coupling enzymatic digestion with nanopore sensing for low-abundance EGFR-L858R mutation detection

Case Report: Peritoneal and small bowel metastasis from lung adenocarcinoma with EGFR L858R mutation

Deciphering the molecular mechanism of enhanced tumor activity of the EGFR variant T790M/L858R using melanoma cell lines

Long-Term Clinical Benefit in EGFR-Mutant Lung Adenocarcinoma With Local Squamous Cell Carcinoma Transformation After EGFR TKI Resistance: A Case Report

Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation

Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report

Case report: EGFR fusion mutation combined with EGFR amplification responds to EGFR-TKI therapy

Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors

Lung adenocarcinoma in a patient with Lynch syndrome: a case report and literature review

Long term survival achieved through combination of almonertinib and pyrotinib in EGFR-mutant/HER2-amplified advanced NSCLC patient: a case report and literature review

The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation

Acquired EGFR L858R mutation following ALK-TKI resistance in lung adenocarcinoma: a Case Report